SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 9, 2010
FURIEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
Registrants telephone number, including area code (919) 456-7800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On December 9, 2010, the Board of Directors (the Board) of Furiex Pharmaceuticals, Inc., appointed Dr. Steve Kaldor as a member of its Board. Dr. Kaldor will hold office until Furiexs 2011 Annual Meeting of Stockholders or until his successor is elected and qualified.
Dr. Kaldor was recommended to the Board and the Nominating and Corporate Governance Committee of the Board (the Committee) by Furiex Chairman Fred Eshelman. The Committees criteria for selecting appropriate candidates include, but are not limited to: personal and professional ethics, integrity and values; commitment to Furiex and its shareholders; an inquisitive and objective perspective and mature judgment; availability to perform all Board and committee responsibilities; and independence. After reviewing him, the Committee recommended Dr. Kaldor for appointment to the Board.
There were no arrangements or understandings between Dr. Kaldor and any other person pursuant to which Dr. Kaldor was appointed as a director and there are no related party transactions between Dr. Kaldor and Furiex. The Board committees that Dr. Kaldor will serve on have not yet been determined. Furiex intends to pay Dr. Kaldor director fees on the same terms as the other independent directors generally.
The press release announcing Dr. Kaldors appointment is attached as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.